ClinicalTrials.gg
CompletedNCT00229437Updated Feb 28, 2012

Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy

A Phase 2 interventional study of TAK-128 and TAK-128 in Diabetic Neuropathies, sponsored by Takeda. Completed at 48 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-02-28.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 158 studies in Diabetic Neuropathies with a site in United States — 12 open to participants now, 17 under way, none of them phase 3. Diabetic Neuropathies · United States.

Enrollment
24th of 145
343 · median 91
Started
2005
with 9 others
Phase 2
47 of 158
1 open now
Registered
21st of 158
by date

Among the 158 studies in Diabetic Neuropathies with a site in United States, this one is the 24th largest by enrollment of the 145 interventional ones that give a count, is one of 10 that started in 2005, is one of 47 in phase 2, and was the 21st registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

12 of the 158 studies in Diabetic Neuropathies with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Diabetic Neuropathies with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of TAK-128, once daily (QD), in treating subjects with diabetic peripheral neuropathy.

Read the detailed description

Polyneuropathy is a frequent complication of diabetes; it affects most individuals after prolonged hyperglycemia, and diabetic neuropathy is very common in the developed world. Chronic, insidious, distal sensorimotor polyneuropathy with autonomic impairment is the most typical form of diabetic neuropathy. Less common, but more florid presentations include autonomic symptoms or painful neuropathy. Although many patients have no or relatively few symptoms, the chronic polyneuropathy and autonomic dysfunction predispose to neurotrophic foot ulceration; consequently, diabetes is the leading cause of amputation today.

Diabetic neuropathy is a dying-back polyneuropathy with distal degeneration of the longest nerve fibers advancing in a centripetal direction. Multiple histopathological changes are observed, but progressive fiber loss is the hallmark of diabetic polyneuropathy. Other important features include endothelial cell basement membrane thickening, segmental demyelination and remyelination, and axonal atrophy. Similar pathological changes are observed in type 1 and type 2 diabetes. The severity of neuropathy as indicated by the stage of nerve fiber loss determines the clinical, electrophysiological, and quantitative sensory threshold features of this disorder. The functional measures of electrophysiological and quantitative sensory thresholds reflect the morphological changes and the clinical features.

Diabetic polyneuropathy is etiologically related to prolonged hyperglycemia with multiple consequences. Although strict glycemic control prevents neuropathy in type 1 patients if maintained for many years, similar interventions in those with type 2 diabetes mellitus are less successful. Type 2 patients may have neuropathy with considerable nerve fiber loss at the time of diagnosis because of unsuspected hyperglycemia in preceding years. Reversal of established neuropathy with strict glycemic control is not certain to occur, even if maintained for many years. Co-morbid disease often interferes with strict management of type 2 diabetes. Even among those with type 1 diabetes, a minority of patients are successful in maintaining prolonged euglycemia.

TAK-128 is a novel synthetic compound being developed as a treatment for diabetic neuropathy.

03

Conditions studied

  • Diabetic Neuropathies

Browse trials for

Keywords

  • Diabetic Mononeuropathy
  • Diabetic Neuralgia
  • Mononeuropathy, Diabetic
  • Neuralgia, Diabetic
  • Diabetic Polyneuropathy
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects of must be nonpregnant, nonlactating and on an acceptable form of .
  • The subject has fasting clinical laboratory evaluations within the normal reference range for the testing laboratory, or if not, the results must be deemed not by the investigator prior to randomization.
  • The subject has type 1 or 2 diabetes mellitus using World Health Organization Criteria.
  • The subject has mild to moderate peripheral neuropathy defined as:

    • Clinical neuropathy score greater than or equal to 2.5 on the Michigan Neuropathy Screening Instrument.
    • Confirmed abnormality of at least 2 nerve conduction study velocity parameters as defined by the Neurological Core Laboratory.
    • Sural sensory nerve potential amplitude greater than or equal to 1 microvolt.
  • The subject's glycosylated is less than or equal to 10%.
  • The subject is on stable diabetic therapy for at least 3 months prior to randomization.
  • The subject is on stable pain medication for at least 6 weeks prior to randomization, if applicable.
  • The subject's creatinine level is less than or equal to 2 mg/dL or 176.8 umol/L.
  • The subject is willing to follow an American Diabetes Association or similar recommended dietary regimen.

Exclusion criteria

Exclusion Criteria:

  • The subject has a history of other neuropathies due to causes other than diabetes such as alcohol abuse liver or renal disease, uremia, toxic exposure, genetic factors, inflammatory demyelinating diseases, monoclonal gammopathies; or endocrine, metabolic or nutritional disorders (included treated or untreated pernicious anemia).
  • The subject has clinical or electrophysiologic evidence of bilateral carpal tunnel syndrome.
  • The subject has a significant skin abnormality or ulcerative changes in their lower extremities.
  • The subject's is greater than 40 kg/m2.
  • The subject's systolic blood pressure is greater than 160 mm Hg or diastolic blood pressure is greater than 95 mm Hg.
  • The subject has a history of myocardial infarction, coronary angioplasty or bypass graft, unstable angina pectoris, , significant , or documented cerebrovascular accident within 6 months prior to Screening, or is Functional Cardiac Classification III or IV.
  • The subject has an level of greater than 1.5 times the , active liver disease, or jaundice.
  • The subject has a significant, actively treated or unstable pulmonary, gastrointestinal, hepatic, hematologic, musculoskeletal, or endocrine (other than diabetes mellitus or stably treated hypothyroidism) disease.
  • The subject has a previous history of cancer, other than basal cell carcinoma, that has not been in remission for at least 5 years prior to the first dose of study drug.
  • The subject has taken lipoic acid, linolenic acid (primrose oil), inositol, topiramate, Acetyl-L-Carnitine, nerve growth factors, or capsaicin within 30 days prior to Screening.
  • The subject has any other serious disease or condition at Screening or at randomization that might affect or make it difficult to successfully manage and follow the subject according to the protocol.
  • The subject has a history of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within the past 2 years.
  • The subject has a known to a compound related to TAK-128.
  • Subjects can not use any of the following prescription medications throughout the duration of the study, including:

    • Lipoic acid
    • Linolenic acid (primrose oil)
    • Inositol
    • Topiramate
    • Acetyl-L-Carnitine
    • Nerve growth factors
    • Capsaicin
  • The subject currently is participating in another study or has participated in an investigational study within the past (30 days or 5 half lives, whichever is longer).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    TAK-128 5 mg QD

    Drug: TAK-128

  • Experimental
    TAK-128 50 mg QD

    Drug: TAK-128

  • Experimental
    TAK-128 100 mg QD

    Drug: TAK-128

  • Placebo comparator
    Placebo QD

    Drug: Placebo

Interventions

  • DrugTAK-128

    TAK-128 5 mg, tablets, orally, once daily for up to 6 months.

  • DrugTAK-128

    TAK-128 50 mg, tablets, orally, once daily for up to 6 months.

  • DrugTAK-128

    TAK-128 100 mg, tablets, orally, once daily for up to 6 months.

  • DrugPlacebo

    TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in composite measure of maximal nerve conduction velocity (Nerve Conduction Studies).

    Time frame: Week 24 or Final Visit

Secondary outcomes

  1. Change from Baseline in the electrophysiologic parameters for individual nerves, including amplitudes (Nerve Conduction Studies).

    Time frame: Week 24 or Final Visit

  2. Change from Baseline in vibration perception threshold measurements (Quantitative Sensory Testing).

    Time frame: Weeks 12, 24 or Final Visit

  3. Change from Baseline in pain scores (Short-Form McGill Pain Questionnaire).

    Time frame: Weeks: 8, 12, 16, 20, 24 or Final Visit

  4. Change from Baseline in the neurological examination (Clinical Neurological Examination).

    Time frame: Weeks 12, 24 or Final Visit

  5. Change from Baseline in quality of life index (SF-36 Health Survey).

    Time frame: Weeks: 8, 12, 16, 20, 24 or Final Visit

07

Study locations

48 sites
  • Mesa, Arizona, United States
  • Peoria, Arizona, United States
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Little Rock, Arkansas, United States
  • Huntington Beach, California, United States
  • La Jolla, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Northridge, California, United States
  • San Francisco, California, United States
  • Torrance, California, United States
  • Tustin, California, United States
  • Aventura, Florida, United States
  • Fort Myers, Florida, United States
  • Hialeah, Florida, United States
  • Miami, Florida, United States
  • Palm Beach Gardens, Florida, United States
  • Plant City, Florida, United States
  • Decatur, Georgia, United States
  • Chicago, Illinois, United States
  • Louisville, Kentucky, United States
  • New Orleans, Louisiana, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Flint, Michigan, United States
  • St. Louis, Missouri, United States
  • Las Vegas, Nevada, United States
  • Elizabeth, New Jersey, United States
  • New Brunswick, New Jersey, United States
  • Buffalo, New York, United States
  • Staten Island, New York, United States
  • Greenville, North Carolina, United States
  • Oklahoma City, Oklahoma, United States
  • Morrisville, Pennsylvania, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Norfolk, Virginia, United States
  • Tacoma, Washington, United States
  • Calgary, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Kingston, Ontario, Canada
  • North Bay, Ontario, Canada
  • Sarina, Ontario, Canada
  • Gatineau, Quebec, Canada
  • Laval, Quebec, Canada
  • Quebec, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2005
First posted
Sep 29, 2005
Start
Mar 2005
Primary completionActual
May 2006
CompletionActual
May 2006
Last update
Feb 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00229437
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 29, 2005
Start date
Mar 2005
Primary completion
May 2006
Completion
May 2006
Last update
Feb 28, 2012

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion